High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas

Bone Marrow Transplantation

Volumn 34, Issue 1, 2004, Pages 37-41

  Kasper, Bernd ^a   Lehnert, T ^b   Bernd, L ^c   Mechtersheimer, G ^a   Goldschmidt, H ^a   Ho, A D ^a   Egerer, G ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b KLINIKUM BREMEN MITTE   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Bone sarcoma; High dose chemotherapy; Peripheral blood stem cell transplantation; Soft tissue sarcoma

Indexed keywords

BUSULFAN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; MESNA; SAMARIUM;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG MEGADOSE; DRUG POTENTIATION; EWING SARCOMA; FEMALE; GRAFT VERSUS HOST REACTION; HEART ARREST; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LIPOSARCOMA; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; ORTHOPEDIC SURGERY; OSTEOSARCOMA; PERIPHERAL NERVE TUMOR; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; THROMBOCYTOPENIA; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SARCOMA; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 3543081513     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704520     Document Type: Article

References (33)

1. Van Glabbeke M, van Oosterom AT, Oosterhuis JW et al. Prognostic factors in advanced soft tissue sarcoma: an analysis of 2185 patients treated with anthracycline-containing first-line regimens - a European Organization for Research and Treatment of Canter Soft Tissue and Bone Sarcoma Group study. J Clin Oncol 1999; 17: 150-157.
2. Edmonson JH, Ryan LM, Blum RG et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993; 11: 1269-1275.
3. Antman KH, Crowley J, Balcerzak SP et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993; 11: 1276-1285.
4. Santoro A, Tursz T, Mouridsen H et al. Doxorubicin versus CyVADic versus ifosfamide plus doxorubicin in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995; 13: 1537-1545.
5. Bui NB, Demaille MC, Chevreau C et al. qMAID vs MAID+25% in adults with advanced soft tissue sarcoma (STS): first results of a randomized study of the FNCLCC Sarcoma Group. Proc Am Soc Clin Oncol 1998; 17: 517a (abstr 1991).
6. Blay JY, van Glabbeke M, Nielsen OS et al. Five-year survivors in patients (pts) with advanced soft tissue sarcoma (ASTS) treated with doxorubicin: a study on 1742 patients (STBSG). Proc Am Soc Clin Oncol 1998; 17: 512a (abstr 1973).
7. Standard-Options-Recommandations Vol 1. Sarcome des Tissus Mous et Ostéosarcomes. Arnette Blackwell: Paris, France, 1995; pp 1-113.
8. Demetri GD, Elias AD. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas: Implications for decision making in the clinic. Hematol Oncol Clin N Am 1995; 9: 765-785.
9. Verweij J, Mouridsen HT, Nielsen OS et al. The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view. Crit Rev Oncol Hematol 1995; 20: 193-201.
10. Rosen G, Forscher C, Lowenbraun S et al. Synovial sarcoma: uniform response of metastases to high dose ifosfamide. Cancer 1994; 73: 2506-2511.
11. Patel SR, Vadhan-Raj S, Papadopolous N et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies - dose-response and schedule dependence. J Clin Oncol 1997; 15: 2378-2384.
12. Le Cesne A, Antoine E, Spielmann M et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995; 13: 1600-1608.
13. Saeter G, Alvegard TA, Monge OR et al. Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma: a Scandinavian Sarcoma Group Phase II Study. Eur J Cancer 1997; 33: 1551-1558.
14. Van Oosterom AT, Verweij J. New drugs for the treatment of sarcomas. Hematol Oncol Clin N Am 1995; 9: 909-925.
15. Budd GT, Metch B, Balcerzak SP et al. High-dose cisplatin for metastatic soft tissue sarcoma. Cancer 1990; 65: 866-869.
16. Jelic S, Kovcin V, Milanovic N et al. Randomised study of high-dose epirubicin versus high-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcoma. Eur J Cancer 1997; 33: 220-225.
17. Reichardt P, Tilgner J, Hohenberger P, Dorken B. Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adultpatients with metastatic or locally advanced soft tissue sarcoma: a phase II study. J Clin Oncol 1998; 16: 1438-1443.
18. Horowitz ME, Kinsella TJ, Wexler LH et al. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. J Clin Oncol 1993; 11: 1911-1918.
19. Burdach S, Jurgens H, Peters C et al. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J Clin Oncol 1993; 11: 1482-1488.
20. Boulad F, Kernan NA, LaQuaglia MP et al. High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing's sarcoma, and undifferentiated sarcoma. J Clin Oncol 1998; 16: 1697-1706.
21. Fagioli F, Aglietta M, Tienghi A et al. High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study. J Clin Oncol 2001; 20: 2150-2156.
22. Sauerbrey A, Bielack S, Kempf-Bielack B et al. High-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (ASCT) as salvage therapy for relapsed osteosarcoma. Bone Marrow Transplant 2001; 27: 933-937.
23. Bokemeyer C, Franzke A, Hartmann JT et al. A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer 1997; 80: 1221-1227.
24. Elias AD, Ayash LJ, Wheeler C et al. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support. Bone Marrow Transplant 1995; 15: 373-379.
25. Dumontet C, Biron P, Bouffet E et al. High dose chemotherapy with ABMT in soft tissue sarcomas: a report of 22 cases. Bone Marrow Transplant 1992; 10: 405-408.
26. Mesia R, Sola C, Lopez Pousa A et al. High-dose chemotherapy and autologous bone marrow transplantation in high-grade metastatic sarcomas. Rev Clin Esp 1994; 194: 960-965.
27. Wiklund T, Saeter G, Strander H et al. The outcome of advanced soft tissue sarcoma patients with complete tumour regression after either chemotherapy alone or chemotherapy plus surgery: the Scandinavian Sarcoma Group experience. Eur J Cancer 1997; 33: 357-361.
28. Seynaeve C, Verweij J. High-dose chemotherapy in adult sarcomas: no standard yet. Semin Oncol 1999; 26: 119-133.
29. Blay JY, Bouhour D, Ray-Coquard I et al. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults. J Clin Oncol 2000; 18: 3643-3650.
30. Antman KH, Elias A. Dana-Farber Cancer Institute studies in advanced sarcoma. Semin Oncol 1990; 17 (Suppl. 2): 7-15.
31. Verweij J. Etoposide for soft tissue sarcomas: fact or fiction. Eur J Cancer 1997; 33: 1527-1528.
32. Durand RE, Goldie JH. Interaction of etoposide and cisplatin in an in vitro tumor model. Cancer Treat Rep 1987; 71: 673-679.
33. Rosti G, Ferrante P, Ledermann J et al. High-dose chemotherapy for solid tumors: results of the EBMT. Crit Rev Oncol Hematol 2002; 41: 129-140.